Pfizer EBIT

The latest EBIT for PFE is $7.1B as of June 2026. That compares with $15B in the prior-year period — down 52.5% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Pfizer's historical trend and sector peers before judging valuation or financial health.

Over the past year, PFE's EBIT moved from $15B to $7.1B — a 52.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Pfizer's operating scale or balance-sheet position.

Against Healthcare companies, PFE currently prints $7.1B for EBIT, while the sector average sits near $110B. That is roughly 93.4% below the sector mean. Large gaps often invite a closer look at Pfizer's growth, margins, and balance sheet.

A EBIT figure of $7.1B for PFE is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting PFE's EBIT ($7.1B), review year-over-year change from $15B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.